Please assess the completion status of the following clinical trial:

Trial Title: Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject has CardioMEMS HF PA Sensor and a commercially-approved HeartMate LVAD (Group A) OR Subject has commercially-approved HeartMate LVAD, is experiencing NYHA class III symptoms, and has had a previous HF hospitalization and meets FDA indications for CardioMEMS. The CardioMEMS PA Sensor must be implanted within 72 hours of consent (Group B)~2. Signed an informed consent form and agreed to provide access to patient and device data (including CardioMEMS Merlin.net data)~3. No connectivity or transmission problems with CardioMEMS~4. On HeartMate LVAD support for at least 3 months~5. Age ≥ 18 years~Exclusion Criteria:~1. Current participation in an investigation that is likely to confound study results or affect study outcome~2. Current participation in the MOMENTUM3 IDE Clinical trial and has not completed the two year follow-up for that trial~3. Inability to perform 6MHW test due to conditions other than heart failure (e.g. severe arthritis, orthopedic issues, amputation etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: Patients with CardioMEMS PA Sensor and HeartMate LVAD prior to study enrollment (Type: None): Patients with CardioMEMS PA Sensor and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS HF System
- Group B: Patients with existing HeartMate LVAD implanted with CardioMEMS PA Sensor post enrollment (Type: None): Patients with a HeartMate LVAD prior to study enrollment who are implanted with a CardioMEMS PA Sensor within 72 hours of study enrollment, will receive hemodynamic management using CardioMEMS HF System

Based on this trial design, predict the completion outcome and termination type (if applicable).